Related Experiment Videos
Multiplex reverse transcriptase-polymerase chain reaction screening in childhood acute myeloblastic leukemia
1Children's Cancer Research Institute (CCRI) and the Ludwig- Boltzmann Institute for Cytogenetic Diagnosis (LBICD), St Anna Children's Hospital, Vienna, Austria.
Blood
|February 7, 2001
Summary
A novel multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) assay detected leukemia-specific gene fusions in 40% of childhood leukemia cases. This molecular technique complements cytogenetics for quality control and minimal residual disease detection.
Area of Science:
- Molecular Biology
- Hematology
- Genetics
Background:
- Childhood acute myeloblastic leukemia (AML) and transient myeloproliferative disorder (TMD) are significant hematologic malignancies.
- Accurate molecular diagnosis is crucial for prognosis and treatment stratification.
Observation:
- A novel multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) assay was developed to detect leukemia-specific gene rearrangements.
- The assay targets 28 fusion genes and over 80 transcript variants, utilizing RNA from cytogenetically prepared cells.
Findings:
- The multiplex RT-PCR assay identified nine different fusion transcripts in 40% of the 60 childhood leukemia cases studied.
- While cytogenetic analysis revealed abnormalities in 78.3% of cases, RT-PCR detected two t(6;11) and MLL/AF6 gene fusions missed by karyotyping.
- Cytogenetics identified 10 other chromosome rearrangements not detectable by the RT-PCR assay.
Implications:
- Multiplex RT-PCR serves as a valuable quality control measure for cytogenetic findings in childhood leukemia.
- This molecular approach is essential for minimal residual disease monitoring.
- Discrepancies between RT-PCR and cytogenetics can lead to the discovery of novel molecular rearrangements.